Form 8-K - Current report:
SEC Accession No. 0000950170-22-011269
Filing Date
2022-06-07
Accepted
2022-06-07 16:05:55
Documents
12
Period of Report
2022-06-03
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axsm-20220603.htm   iXBRL 8-K 99528
  Complete submission text file 0000950170-22-011269.txt   214273

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axsm-20220603_lab.xml EX-101.LAB 12798
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axsm-20220603_pre.xml EX-101.PRE 9441
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axsm-20220603.xsd EX-101.SCH 2451
6 EXTRACTED XBRL INSTANCE DOCUMENT axsm-20220603_htm.xml XML 4540
Mailing Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007
Business Address 22 CORTLANDT STREET, 16TH FLOOR NEW YORK NY 10007 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37635 | Film No.: 221001278
SIC: 2834 Pharmaceutical Preparations